Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q3 2015 · 10-Q
Revenue—
Net Income-$3.59M-$3.59MN/M vs Q3 2014 EPS Diluted-$0.14-$0.14N/M vs Q3 2014 Operating Income-$3,599,000N/M Operating Cash Flowderived-$2,843,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,842,000— ended Sep 30, 2015 · filed Nov 12, 2015 · 43 d after period end